Figure 1:
PREOPERATIVE LABORATORY_
| Variables | Non-complication (n=525) | Complication (n=42) | P-value |
|---|---|---|---|
| HgbA1c | 6.53 (0.65) | 6.74 (0.74) | 0.499 |
| Hgb | 13.77 (1.40) | 13.52 (1.52) | 0.282 |
| Albumin | 4.40 [4.20–4.60] | 4.40 [4.10–4.50] | 0.110 |
| Total protein | 7.10 [6.80–7.40] | 7.00 [6.80–7.30] | 0.929 |
MULTIVARIATE ANALYSIS_
| Variables | Odds ratio (95% CI) | P-value |
|---|---|---|
| Model 1: ECW/TBW | ||
| ECW/TBW z-score | 1.65 (1.17–2.31) | 0.004* |
| PBF | 0.96 (0.93–1.00) | 0.048* |
| Immunocompromised | 2.22 (0.95–5.20) | 0.065 |
| Albumin | 0.48 (0.15–1.60) | 0.233 |
| Model 2: ECW/ICW | ||
| ECW/ICW z-score | 1.61 (1.15–2.23) | 0.005* |
| PBF | 0.97 (0.93–1.00) | 0.051 |
| Immunocompromised | 2.23 (0.95–5.21) | 0.064 |
| Albumin | 0.47 (0.14–1.57) | 0.221 |
| Model 3: Phase Angle | ||
| Whole body ϕ | 0.58 (0.37–0.91) | 0.018* |
| PBF | 0.96 (0.93–1.00) | 0.045* |
| Immunocompromised | 2.16 (0.93–5.06) | 0.075 |
| Albumin | 0.43 (0.13–1.42) | 0.167 |
| Model 4: BMI | ||
| BMI | 1.65 (0.91–1.01) | 0.200 |
| Immunocompromised | 2.31 (0.98–5.47) | 0.063 |
| Albumin | 0.49 (0.15–1.67) | 0.067 |
ROC ANALYSIS_
| Models | AUC (95% CI) | P-value |
|---|---|---|
| Model 1: ECW/TBW | 0.71 (0.62–0.79) | <0.001 |
| Model 2: ECW/ICW | 0.70 (0.62–0.79) | <0.001 |
| Model 3: Phase Angle | 0.69 (0.60–0.79) | <0.001 |
| Model 4: BMI | 0.61 (0.51–0.71) | 0.032 |
POSTOPERATIVE COMPLICATIONS_
| Type | Total (n=42) | TKA (n=25) | THA (n=17) |
|---|---|---|---|
| Deep joint infection | 16 | 10 | 6 |
| Delayed surgical wound healing | 4 | 2 | 2 |
| Dislocation | 8 | 0 | 8 |
| Arthrofibrosis* | 4 | 4 | 0 |
| Revision surgery | 17 | 9 | 8 |
| ED visits** | 4 | 2 | 2 |
PATIENT CHARACTERISTICS_
| TJA complications | ||||
|---|---|---|---|---|
| Variables | Total (n=567) | Non-complication (n=525) | Complication (n=42) | P-value |
| Age, median (IQR) | 66 [58–72] | 67 [59–73] | 65 [58–71] | 0.588 |
| Sex, female | 316 (55.7) | 293 (55.8) | 23 (54.8) | 0.951 |
| TKA | 311 (54.9) | 286 (54.5) | 25 (59.5) | 0.527 |
| Race | 0.165 | |||
| White | 529 (93.3) | 489 (93.1) | 40 (95.2) | |
| Black | 21 (3.7) | 21 (4.0) | 0 (0.0) | |
| Hispanic | 8 (1.41) | 7 (1.3) | 1 (2.4) | |
| Asian | 6 (1.06) | 6 (1.1) | 0 (0.0) | |
| Native Hawaiian/Pacific Islander | 2 (0.35) | 1 (0.2) | 1 (2.4) | |
| Declined to answer | 1 (0.18) | 1 (0.2) | 0 (0.0) | |
| Diabetes | 103 (18.2) | 98 (18.7) | 5 (11.9) | 0.272 |
| HTN | 319 (56.3) | 297 (56.6) | 22 (52.4) | 0.598 |
| Current smoker | 9 (1.59) | 8 (1.5) | 1 (2.4) | 0.669 |
| Immunocompromised | 61 (10.8) | 53 (10.1) | 8 (19.0) | 0.072 |
| Chronic kidney disease | 0.977 | |||
| Stage 1 | 3 (0.53) | 3 (0.6) | 0 (0.0) | |
| Stage 2 | 11 (1.94) | 10 (1.9) | 1 (2.4) | |
| Stage 3 | 33 (5.82) | 31 (5.9) | 2 (4.8) | |
| Stage 4 | 4 (0.71) | 4 (0.8) | 0 (0.0) | |
| Stage 5 | 1 (0.18) | 1 (0.2) | 0 (0.0) | |
| Lower extremities lymphedema | 9 (1.59) | 7 (1.3) | 2 (4.8) | 0.087 |
| Lower extremities edema | 48 (8.47) | 45 (8.6) | 3 (7.1) | 0.749 |
UNIVARIATE ANALYSIS_
| Variables | Non-complication (n=525) | Complication (n=42) | P-value | Adjusted P-value (FDR) |
|---|---|---|---|---|
| ECW/ICW | 0.647 [0.632–0.666] | 0.657 [0.644–0.673] | 0.012* | 0.042* |
| ECW/TBW | 0.393 [0.387–0.400] | 0.396 [0.391–0.403] | 0.011* | 0.042* |
| SMI | 8.30 [7.20–9.30] | 8.40 [6.80–9.55] | 0.651 | 0.750 |
| PBF | 39.50 [32.90–46.80] | 38.50 [31.30–46.60] | 0.506 | 0.708 |
| VFA | 190 [137–238] | 194 [129–234] | 0.750 | 0.750 |
| Phase angle** | 4.80 [4.30–5.40] | 4.65 [4.13–5.00] | 0.039* | 0.091 |
| BMI | 32.60 [28.30–37.70] | 32.00 [26.20–37.70] | 0.474 | 0.708 |